In dit groepsproject hebben we onderzocht in hoeverre vrouwelijke patiënten met RRMMS die medicamenteuze therapie ondergaan meer gerapporteerde Covid-19 symptomenen evaren in vergelijking met patiënten zonder behandeling.
H0: Er is geen verschil tussen vrouwelijke patiënten met RRMS die medicamenteuze therapie ondergaan vergeleken met vrouwen met RRMS zonder medicamenteuze therapie op basis van gerapporteerde COVID-19 symptomen. Ha: Er is een verschil tussen vrouwelijke patiënten met RRMS die medicamenteuze therapie ondergaan vergeleken met vrouwen met RRMS zonder medicamenteuze therapie op basis van gerapporteerde COVID-19 symptomen
Beschrijven van het voorkomen van covid-19 symptomen bij vrouwen met RRMS.
Beschrijven van het medicatiegebruik bij vrouwen met RRMS.
Het verband onderzoeken tussen meer gerapporteerde covid-19 symptomen en het gebruik van een medicamenteuze behandeling uit de databank van GDSI_OpenDataset_Final.
Groepsleden:
An-Sofie
Dennis Hertoghe
Dries Nassen
We hebben gewerkt in verschillende stappen:
Inladen van de data en sorteren op enkel vrouwen met RRMMS.
Beschrijvende analyse over hoeveel vrouwen met RRMMS Covid-19 symptomen hebben en welke suspected en confirmed zijn. Daarnaast verschillende comorbiditeiten van deze vrouwen en hun medicatiegebruik.
Alle data die “not answered” zijn aanpassen naar “neen” gerelateerd aan alle variabele binnen de categorie Covid-19 symptomen.
Alle kollomen “Yes” en “No” worden omgezet naar “0” of “1”, bij alle variabele binnen de categorie Covid-19 symptomen.
Dataset opstellen met enkel de kolommen van Covid-19 symptomen en deze kolomnamen versimpelen.
Starten met hiërarchisch clusteren tot we een visualisatie bekomen (Dendogram).
Medicatie TO DO !!
Voer test statistiek uit: Chi-kwadraat voor goodness of fit met betrekking tot de clustering van Covid-19 symptomen.
Regressie TO DO !!
Bespreking resultaten in het dashboard.
female male
904 237
other progressive_MS relapsing_remitting
131 104 906
other progressive_MS relapsing_remitting
female 93 72 739
male 38 32 167
no yes
7 489 243
no yes
562 171 6
no yes
522 217
no yes
563 173 3
no yes
560 175 4
no yes
558 169 12
no yes
556 153 30
no yes
565 155 19
no yes
560 160 19
no yes
565 166 8
no yes
562 161 16
1
160
currently not using any DMT
82 59
currently on alemtuzumab currently on another drug not listed
8 117
currently on cladribine currently on dimethyl fumarate
29 101
currently on fingolimod currently on glatiramer
90 43
currently on interferon currently on natalizumab
59 49
currently on ocrelizumab currently on rituximab
52 8
currently on teriflunomide
42
no yes
7 489 243
no yes
546 54 139
no yes
576 89 74
no yes
549 31 159
no yes
567 102 70
no yes
557 68 114
no yes
544 100 95
no yes
576 103 60
no yes
557 57 125
no yes
586 143 10
no yes
560 64 115
## Column {data-width=“250”}
chills dry_cough fatigue fever
1 2 2 1
loss_smell_taste nasal_congestion pain pneumonia
3 2 2 4
shortness_breath sore_throat
1 2
clusters
1 2 3 4
3 5 1 1
clusters
1 2 3 4
0.3 0.5 0.1 0.1
clusters
1 2 3 4
3 5 1 1
Chi-squared test for given probabilities
data: cluster_counts
X-squared = 4.4, df = 3, p-value = 0.2214
Call:
glm(formula = chills ~ dmt_type_overall + symptoom_cluster1 +
symptoom_cluster2 + symptoom_cluster3, family = "binomial",
data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -37.7215 2433.4455
dmt_type_overallcurrently not using any DMT 0.7388 0.8001
dmt_type_overallcurrently on alemtuzumab 15.1555 17212.7910
dmt_type_overallcurrently on another drug not listed 0.1201 0.7571
dmt_type_overallcurrently on cladribine 0.6383 1.0806
dmt_type_overallcurrently on dimethyl fumarate -0.3634 0.7861
dmt_type_overallcurrently on fingolimod -0.4860 0.7933
dmt_type_overallcurrently on glatiramer 0.4678 0.9101
dmt_type_overallcurrently on interferon 0.6457 0.9762
dmt_type_overallcurrently on natalizumab -0.1613 0.9179
dmt_type_overallcurrently on ocrelizumab -1.4340 0.9122
dmt_type_overallcurrently on rituximab 0.2442 1.5575
dmt_type_overallcurrently on teriflunomide 0.1229 0.9582
symptoom_cluster1 20.3459 1681.9380
symptoom_cluster2 17.1315 1758.6197
symptoom_cluster3 1.0268 0.4480
z value Pr(>|z|)
(Intercept) -0.016 0.9876
dmt_type_overallcurrently not using any DMT 0.923 0.3558
dmt_type_overallcurrently on alemtuzumab 0.001 0.9993
dmt_type_overallcurrently on another drug not listed 0.159 0.8739
dmt_type_overallcurrently on cladribine 0.591 0.5548
dmt_type_overallcurrently on dimethyl fumarate -0.462 0.6439
dmt_type_overallcurrently on fingolimod -0.613 0.5401
dmt_type_overallcurrently on glatiramer 0.514 0.6073
dmt_type_overallcurrently on interferon 0.661 0.5083
dmt_type_overallcurrently on natalizumab -0.176 0.8605
dmt_type_overallcurrently on ocrelizumab -1.572 0.1159
dmt_type_overallcurrently on rituximab 0.157 0.8754
dmt_type_overallcurrently on teriflunomide 0.128 0.8980
symptoom_cluster1 0.012 0.9903
symptoom_cluster2 0.010 0.9922
symptoom_cluster3 2.292 0.0219 *
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 480.91 on 738 degrees of freedom
Residual deviance: 188.15 on 723 degrees of freedom
AIC: 220.15
Number of Fisher Scoring iterations: 21
Call:
glm(formula = dry_cough ~ dmt_type_overall + symptoom_cluster1 +
symptoom_cluster2 + symptoom_cluster3, family = "binomial",
data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -31.2872 1514.4174
dmt_type_overallcurrently not using any DMT -0.3257 0.7053
dmt_type_overallcurrently on alemtuzumab 9.7212 10445.5918
dmt_type_overallcurrently on another drug not listed -0.4952 0.6388
dmt_type_overallcurrently on cladribine -0.6878 0.9113
dmt_type_overallcurrently on dimethyl fumarate -1.1560 0.6827
dmt_type_overallcurrently on fingolimod -0.6944 0.6458
dmt_type_overallcurrently on glatiramer 0.7852 0.9360
dmt_type_overallcurrently on interferon -1.5712 0.7414
dmt_type_overallcurrently on natalizumab -1.1202 0.6984
dmt_type_overallcurrently on ocrelizumab 0.2889 0.7740
dmt_type_overallcurrently on rituximab 14.5448 1071.8416
dmt_type_overallcurrently on teriflunomide -1.0404 0.7895
symptoom_cluster1 0.4997 0.3069
symptoom_cluster2 31.8901 1514.4174
symptoom_cluster3 0.6295 0.3636
z value Pr(>|z|)
(Intercept) -0.021 0.9835
dmt_type_overallcurrently not using any DMT -0.462 0.6443
dmt_type_overallcurrently on alemtuzumab 0.001 0.9993
dmt_type_overallcurrently on another drug not listed -0.775 0.4382
dmt_type_overallcurrently on cladribine -0.755 0.4504
dmt_type_overallcurrently on dimethyl fumarate -1.693 0.0904 .
dmt_type_overallcurrently on fingolimod -1.075 0.2823
dmt_type_overallcurrently on glatiramer 0.839 0.4015
dmt_type_overallcurrently on interferon -2.119 0.0341 *
dmt_type_overallcurrently on natalizumab -1.604 0.1087
dmt_type_overallcurrently on ocrelizumab 0.373 0.7090
dmt_type_overallcurrently on rituximab 0.014 0.9892
dmt_type_overallcurrently on teriflunomide -1.318 0.1875
symptoom_cluster1 1.628 0.1035
symptoom_cluster2 0.021 0.9832
symptoom_cluster3 1.731 0.0834 .
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 714.53 on 738 degrees of freedom
Residual deviance: 272.49 on 723 degrees of freedom
AIC: 304.49
Number of Fisher Scoring iterations: 20
Call:
glm(formula = fatigue ~ dmt_type_overall + symptoom_cluster1 +
symptoom_cluster2 + symptoom_cluster3, family = "binomial",
data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -3.078e+01 1.510e+03
dmt_type_overallcurrently not using any DMT -7.616e-01 7.585e-01
dmt_type_overallcurrently on alemtuzumab 9.217e+00 1.044e+04
dmt_type_overallcurrently on another drug not listed 2.738e-01 7.443e-01
dmt_type_overallcurrently on cladribine -5.066e-01 1.025e+00
dmt_type_overallcurrently on dimethyl fumarate -1.031e+00 7.485e-01
dmt_type_overallcurrently on fingolimod -9.853e-02 7.320e-01
dmt_type_overallcurrently on glatiramer -8.108e-01 8.272e-01
dmt_type_overallcurrently on interferon 1.532e-01 8.745e-01
dmt_type_overallcurrently on natalizumab 2.446e-01 8.163e-01
dmt_type_overallcurrently on ocrelizumab -2.242e+00 7.747e-01
dmt_type_overallcurrently on rituximab 1.405e+01 1.069e+03
dmt_type_overallcurrently on teriflunomide -1.421e+00 8.377e-01
symptoom_cluster1 9.504e-01 3.386e-01
symptoom_cluster2 3.143e+01 1.510e+03
symptoom_cluster3 8.376e-01 4.132e-01
z value Pr(>|z|)
(Intercept) -0.020 0.98374
dmt_type_overallcurrently not using any DMT -1.004 0.31532
dmt_type_overallcurrently on alemtuzumab 0.001 0.99930
dmt_type_overallcurrently on another drug not listed 0.368 0.71303
dmt_type_overallcurrently on cladribine -0.494 0.62116
dmt_type_overallcurrently on dimethyl fumarate -1.378 0.16830
dmt_type_overallcurrently on fingolimod -0.135 0.89292
dmt_type_overallcurrently on glatiramer -0.980 0.32699
dmt_type_overallcurrently on interferon 0.175 0.86095
dmt_type_overallcurrently on natalizumab 0.300 0.76444
dmt_type_overallcurrently on ocrelizumab -2.894 0.00381 **
dmt_type_overallcurrently on rituximab 0.013 0.98951
dmt_type_overallcurrently on teriflunomide -1.697 0.08976 .
symptoom_cluster1 2.807 0.00500 **
symptoom_cluster2 0.021 0.98340
symptoom_cluster3 2.027 0.04265 *
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 769.61 on 738 degrees of freedom
Residual deviance: 235.20 on 723 degrees of freedom
AIC: 267.2
Number of Fisher Scoring iterations: 20
Call:
glm(formula = fever ~ dmt_type_overall + symptoom_cluster1 +
symptoom_cluster2 + symptoom_cluster3, family = "binomial",
data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -2.214e+01 1.191e+03
dmt_type_overallcurrently not using any DMT 2.734e-01 7.830e-01
dmt_type_overallcurrently on alemtuzumab 5.695e-01 1.040e+04
dmt_type_overallcurrently on another drug not listed 1.122e+00 7.983e-01
dmt_type_overallcurrently on cladribine -8.273e-02 1.043e+00
dmt_type_overallcurrently on dimethyl fumarate 3.209e-01 7.939e-01
dmt_type_overallcurrently on fingolimod 1.028e+00 8.134e-01
dmt_type_overallcurrently on glatiramer 6.096e-02 9.028e-01
dmt_type_overallcurrently on interferon 6.628e-01 9.796e-01
dmt_type_overallcurrently on natalizumab -9.474e-04 9.026e-01
dmt_type_overallcurrently on ocrelizumab 1.435e+00 9.999e-01
dmt_type_overallcurrently on rituximab 2.643e-01 1.560e+00
dmt_type_overallcurrently on teriflunomide 1.392e-01 9.616e-01
symptoom_cluster1 2.280e+01 1.191e+03
symptoom_cluster2 -9.257e-01 1.247e+00
symptoom_cluster3 1.063e+00 4.698e-01
z value Pr(>|z|)
(Intercept) -0.019 0.9852
dmt_type_overallcurrently not using any DMT 0.349 0.7270
dmt_type_overallcurrently on alemtuzumab 0.000 1.0000
dmt_type_overallcurrently on another drug not listed 1.405 0.1599
dmt_type_overallcurrently on cladribine -0.079 0.9368
dmt_type_overallcurrently on dimethyl fumarate 0.404 0.6860
dmt_type_overallcurrently on fingolimod 1.263 0.2064
dmt_type_overallcurrently on glatiramer 0.068 0.9462
dmt_type_overallcurrently on interferon 0.677 0.4987
dmt_type_overallcurrently on natalizumab -0.001 0.9992
dmt_type_overallcurrently on ocrelizumab 1.436 0.1511
dmt_type_overallcurrently on rituximab 0.169 0.8654
dmt_type_overallcurrently on teriflunomide 0.145 0.8849
symptoom_cluster1 0.019 0.9847
symptoom_cluster2 -0.743 0.4578
symptoom_cluster3 2.264 0.0236 *
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 567.00 on 738 degrees of freedom
Residual deviance: 185.45 on 723 degrees of freedom
AIC: 217.45
Number of Fisher Scoring iterations: 20
Call:
glm(formula = loss_smell_taste ~ dmt_type_overall + symptoom_cluster1 +
symptoom_cluster2 + symptoom_cluster3, family = "binomial",
data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -2.657e+01 4.000e+04
dmt_type_overallcurrently not using any DMT -3.548e-13 6.110e+04
dmt_type_overallcurrently on alemtuzumab -9.917e-13 1.321e+05
dmt_type_overallcurrently on another drug not listed -7.615e-13 5.140e+04
dmt_type_overallcurrently on cladribine -2.463e-12 7.699e+04
dmt_type_overallcurrently on dimethyl fumarate -7.915e-13 5.303e+04
dmt_type_overallcurrently on fingolimod -1.908e-12 5.457e+04
dmt_type_overallcurrently on glatiramer -6.543e-13 6.723e+04
dmt_type_overallcurrently on interferon -2.619e-12 6.082e+04
dmt_type_overallcurrently on natalizumab -1.856e-12 6.470e+04
dmt_type_overallcurrently on ocrelizumab 3.301e-13 6.327e+04
dmt_type_overallcurrently on rituximab -1.729e-12 1.321e+05
dmt_type_overallcurrently on teriflunomide -1.419e-12 6.767e+04
symptoom_cluster1 8.463e-12 4.872e+04
symptoom_cluster2 -5.592e-12 4.425e+04
symptoom_cluster3 5.313e+01 5.358e+04
z value Pr(>|z|)
(Intercept) -0.001 0.999
dmt_type_overallcurrently not using any DMT 0.000 1.000
dmt_type_overallcurrently on alemtuzumab 0.000 1.000
dmt_type_overallcurrently on another drug not listed 0.000 1.000
dmt_type_overallcurrently on cladribine 0.000 1.000
dmt_type_overallcurrently on dimethyl fumarate 0.000 1.000
dmt_type_overallcurrently on fingolimod 0.000 1.000
dmt_type_overallcurrently on glatiramer 0.000 1.000
dmt_type_overallcurrently on interferon 0.000 1.000
dmt_type_overallcurrently on natalizumab 0.000 1.000
dmt_type_overallcurrently on ocrelizumab 0.000 1.000
dmt_type_overallcurrently on rituximab 0.000 1.000
dmt_type_overallcurrently on teriflunomide 0.000 1.000
symptoom_cluster1 0.000 1.000
symptoom_cluster2 0.000 1.000
symptoom_cluster3 0.001 0.999
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 4.1631e+02 on 738 degrees of freedom
Residual deviance: 4.2874e-09 on 723 degrees of freedom
AIC: 32
Number of Fisher Scoring iterations: 25
Call:
glm(formula = nasal_congestion ~ dmt_type_overall + symptoom_cluster1 +
symptoom_cluster2 + symptoom_cluster3, family = "binomial",
data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -2.034e+01 7.782e+02
dmt_type_overallcurrently not using any DMT -3.410e-01 6.251e-01
dmt_type_overallcurrently on alemtuzumab -2.231e-01 6.317e+03
dmt_type_overallcurrently on another drug not listed 1.386e-01 5.810e-01
dmt_type_overallcurrently on cladribine -9.410e-01 8.636e-01
dmt_type_overallcurrently on dimethyl fumarate 1.955e-01 6.348e-01
dmt_type_overallcurrently on fingolimod -9.843e-01 5.969e-01
dmt_type_overallcurrently on glatiramer -6.833e-01 7.139e-01
dmt_type_overallcurrently on interferon -6.311e-01 6.817e-01
dmt_type_overallcurrently on natalizumab -7.596e-01 6.535e-01
dmt_type_overallcurrently on ocrelizumab -2.040e-04 6.466e-01
dmt_type_overallcurrently on rituximab -4.257e-01 1.497e+00
dmt_type_overallcurrently on teriflunomide -3.898e-01 7.410e-01
symptoom_cluster1 1.687e-01 2.952e-01
symptoom_cluster2 2.060e+01 7.782e+02
symptoom_cluster3 1.218e-01 3.282e-01
z value Pr(>|z|)
(Intercept) -0.026 0.9791
dmt_type_overallcurrently not using any DMT -0.545 0.5854
dmt_type_overallcurrently on alemtuzumab 0.000 1.0000
dmt_type_overallcurrently on another drug not listed 0.239 0.8115
dmt_type_overallcurrently on cladribine -1.090 0.2759
dmt_type_overallcurrently on dimethyl fumarate 0.308 0.7581
dmt_type_overallcurrently on fingolimod -1.649 0.0991 .
dmt_type_overallcurrently on glatiramer -0.957 0.3385
dmt_type_overallcurrently on interferon -0.926 0.3545
dmt_type_overallcurrently on natalizumab -1.162 0.2451
dmt_type_overallcurrently on ocrelizumab 0.000 0.9997
dmt_type_overallcurrently on rituximab -0.284 0.7762
dmt_type_overallcurrently on teriflunomide -0.526 0.5989
symptoom_cluster1 0.572 0.5676
symptoom_cluster2 0.026 0.9789
symptoom_cluster3 0.371 0.7105
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 638.98 on 738 degrees of freedom
Residual deviance: 299.38 on 723 degrees of freedom
AIC: 331.38
Number of Fisher Scoring iterations: 19
Call:
glm(formula = pain ~ dmt_type_overall + symptoom_cluster1 + symptoom_cluster2 +
symptoom_cluster3, family = "binomial", data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -32.5505 1526.0814
dmt_type_overallcurrently not using any DMT 0.7734 0.6429
dmt_type_overallcurrently on alemtuzumab 10.9844 10447.2893
dmt_type_overallcurrently on another drug not listed 0.5584 0.5811
dmt_type_overallcurrently on cladribine 0.1313 0.8498
dmt_type_overallcurrently on dimethyl fumarate 0.9632 0.6490
dmt_type_overallcurrently on fingolimod 0.6053 0.5941
dmt_type_overallcurrently on glatiramer 0.2403 0.7163
dmt_type_overallcurrently on interferon -0.2193 0.6951
dmt_type_overallcurrently on natalizumab 1.2438 0.6825
dmt_type_overallcurrently on ocrelizumab -0.6662 0.6749
dmt_type_overallcurrently on rituximab 15.7930 1080.2646
dmt_type_overallcurrently on teriflunomide 0.9660 0.7747
symptoom_cluster1 0.5797 0.3009
symptoom_cluster2 31.8408 1526.0813
symptoom_cluster3 0.3805 0.3403
z value Pr(>|z|)
(Intercept) -0.021 0.9830
dmt_type_overallcurrently not using any DMT 1.203 0.2290
dmt_type_overallcurrently on alemtuzumab 0.001 0.9992
dmt_type_overallcurrently on another drug not listed 0.961 0.3366
dmt_type_overallcurrently on cladribine 0.155 0.8772
dmt_type_overallcurrently on dimethyl fumarate 1.484 0.1378
dmt_type_overallcurrently on fingolimod 1.019 0.3083
dmt_type_overallcurrently on glatiramer 0.335 0.7373
dmt_type_overallcurrently on interferon -0.316 0.7523
dmt_type_overallcurrently on natalizumab 1.822 0.0684 .
dmt_type_overallcurrently on ocrelizumab -0.987 0.3235
dmt_type_overallcurrently on rituximab 0.015 0.9883
dmt_type_overallcurrently on teriflunomide 1.247 0.2124
symptoom_cluster1 1.927 0.0540 .
symptoom_cluster2 0.021 0.9834
symptoom_cluster3 1.118 0.2635
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 671.80 on 738 degrees of freedom
Residual deviance: 286.04 on 723 degrees of freedom
AIC: 318.04
Number of Fisher Scoring iterations: 20
Call:
glm(formula = pneumonia ~ dmt_type_overall + symptoom_cluster1 +
symptoom_cluster2 + symptoom_cluster3, family = "binomial",
data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -36.3295 3840.4430
dmt_type_overallcurrently not using any DMT -19.6104 8882.2680
dmt_type_overallcurrently on alemtuzumab 12.7635 28355.3396
dmt_type_overallcurrently on another drug not listed 0.6760 1.2577
dmt_type_overallcurrently on cladribine -19.1139 12278.3740
dmt_type_overallcurrently on dimethyl fumarate -0.3252 1.4721
dmt_type_overallcurrently on fingolimod 0.8992 1.2963
dmt_type_overallcurrently on glatiramer 0.3834 1.5231
dmt_type_overallcurrently on interferon -18.5547 8482.6306
dmt_type_overallcurrently on natalizumab -18.9422 9538.3917
dmt_type_overallcurrently on ocrelizumab -19.3156 9235.5279
dmt_type_overallcurrently on rituximab -19.1561 23736.6538
dmt_type_overallcurrently on teriflunomide 0.6742 1.5523
symptoom_cluster1 18.5375 2677.3437
symptoom_cluster2 15.1054 2753.3333
symptoom_cluster3 0.4590 0.8074
z value Pr(>|z|)
(Intercept) -0.009 0.992
dmt_type_overallcurrently not using any DMT -0.002 0.998
dmt_type_overallcurrently on alemtuzumab 0.000 1.000
dmt_type_overallcurrently on another drug not listed 0.537 0.591
dmt_type_overallcurrently on cladribine -0.002 0.999
dmt_type_overallcurrently on dimethyl fumarate -0.221 0.825
dmt_type_overallcurrently on fingolimod 0.694 0.488
dmt_type_overallcurrently on glatiramer 0.252 0.801
dmt_type_overallcurrently on interferon -0.002 0.998
dmt_type_overallcurrently on natalizumab -0.002 0.998
dmt_type_overallcurrently on ocrelizumab -0.002 0.998
dmt_type_overallcurrently on rituximab -0.001 0.999
dmt_type_overallcurrently on teriflunomide 0.434 0.664
symptoom_cluster1 0.007 0.994
symptoom_cluster2 0.005 0.996
symptoom_cluster3 0.569 0.570
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 105.918 on 738 degrees of freedom
Residual deviance: 61.428 on 723 degrees of freedom
AIC: 93.428
Number of Fisher Scoring iterations: 22
Call:
glm(formula = sore_throat ~ dmt_type_overall + symptoom_cluster1 +
symptoom_cluster2 + symptoom_cluster3, family = "binomial",
data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -3.207e+01 1.520e+03
dmt_type_overallcurrently not using any DMT 2.374e-02 6.254e-01
dmt_type_overallcurrently on alemtuzumab 1.050e+01 1.045e+04
dmt_type_overallcurrently on another drug not listed -3.580e-01 5.722e-01
dmt_type_overallcurrently on cladribine -1.308e+00 9.381e-01
dmt_type_overallcurrently on dimethyl fumarate -4.385e-01 6.212e-01
dmt_type_overallcurrently on fingolimod -1.105e-01 5.858e-01
dmt_type_overallcurrently on glatiramer -1.693e-02 7.129e-01
dmt_type_overallcurrently on interferon -1.049e+00 7.077e-01
dmt_type_overallcurrently on natalizumab -1.477e-01 6.473e-01
dmt_type_overallcurrently on ocrelizumab -6.149e-01 6.453e-01
dmt_type_overallcurrently on rituximab 1.532e+01 1.076e+03
dmt_type_overallcurrently on teriflunomide 1.318e+00 9.016e-01
symptoom_cluster1 -1.102e-01 2.981e-01
symptoom_cluster2 3.252e+01 1.520e+03
symptoom_cluster3 -4.485e-01 3.316e-01
z value Pr(>|z|)
(Intercept) -0.021 0.983
dmt_type_overallcurrently not using any DMT 0.038 0.970
dmt_type_overallcurrently on alemtuzumab 0.001 0.999
dmt_type_overallcurrently on another drug not listed -0.626 0.532
dmt_type_overallcurrently on cladribine -1.395 0.163
dmt_type_overallcurrently on dimethyl fumarate -0.706 0.480
dmt_type_overallcurrently on fingolimod -0.189 0.850
dmt_type_overallcurrently on glatiramer -0.024 0.981
dmt_type_overallcurrently on interferon -1.483 0.138
dmt_type_overallcurrently on natalizumab -0.228 0.819
dmt_type_overallcurrently on ocrelizumab -0.953 0.341
dmt_type_overallcurrently on rituximab 0.014 0.989
dmt_type_overallcurrently on teriflunomide 1.462 0.144
symptoom_cluster1 -0.370 0.712
symptoom_cluster2 0.021 0.983
symptoom_cluster3 -1.352 0.176
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 635.59 on 738 degrees of freedom
Residual deviance: 292.88 on 723 degrees of freedom
AIC: 324.88
Number of Fisher Scoring iterations: 20
Call:
glm(formula = shortness_breath ~ dmt_type_overall + symptoom_cluster1 +
symptoom_cluster2 + symptoom_cluster3, family = "binomial",
data = vrouwenRRMS)
Coefficients:
Estimate Std. Error
(Intercept) -33.2050 2333.0830
dmt_type_overallcurrently not using any DMT -0.4768 0.7810
dmt_type_overallcurrently on alemtuzumab 10.6389 17198.8893
dmt_type_overallcurrently on another drug not listed -0.9213 0.7627
dmt_type_overallcurrently on cladribine -0.0928 1.0698
dmt_type_overallcurrently on dimethyl fumarate -1.2596 0.7919
dmt_type_overallcurrently on fingolimod -1.4977 0.8045
dmt_type_overallcurrently on glatiramer -0.4326 0.9088
dmt_type_overallcurrently on interferon -1.3804 0.9785
dmt_type_overallcurrently on natalizumab -0.6553 0.9088
dmt_type_overallcurrently on ocrelizumab -1.8365 0.9108
dmt_type_overallcurrently on rituximab 15.5987 1651.5823
dmt_type_overallcurrently on teriflunomide -1.9698 1.0451
symptoom_cluster1 33.2772 2333.0832
symptoom_cluster2 0.8412 1.2358
symptoom_cluster3 -0.3680 0.4219
z value Pr(>|z|)
(Intercept) -0.014 0.9886
dmt_type_overallcurrently not using any DMT -0.610 0.5416
dmt_type_overallcurrently on alemtuzumab 0.001 0.9995
dmt_type_overallcurrently on another drug not listed -1.208 0.2271
dmt_type_overallcurrently on cladribine -0.087 0.9309
dmt_type_overallcurrently on dimethyl fumarate -1.591 0.1117
dmt_type_overallcurrently on fingolimod -1.862 0.0626 .
dmt_type_overallcurrently on glatiramer -0.476 0.6341
dmt_type_overallcurrently on interferon -1.411 0.1583
dmt_type_overallcurrently on natalizumab -0.721 0.4709
dmt_type_overallcurrently on ocrelizumab -2.016 0.0438 *
dmt_type_overallcurrently on rituximab 0.009 0.9925
dmt_type_overallcurrently on teriflunomide -1.885 0.0595 .
symptoom_cluster1 0.014 0.9886
symptoom_cluster2 0.681 0.4961
symptoom_cluster3 -0.872 0.3830
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 463.10 on 738 degrees of freedom
Residual deviance: 192.88 on 723 degrees of freedom
AIC: 224.88
Number of Fisher Scoring iterations: 21
Onze discriptieve analyse toonden aan dat een aanzienlijk aantal vrouwelijke RRMMS patiënten Covid-19 symptomen rapporteerden. Deze symptomen varieerden van vermoeidheid en keelpijn tot ernstige symptomen zoals kortademigheid en pneumonie. De clusteringanalyse liet zien dat er een duidelijke groeping van symptomen was. Variabele (“not answered”) werden omgezet naar (“no”) wat mogelijks heeft geleidt tot onderschatting van symptomen. Daarnaast is er een observationele bias aangezien de studie ook zelf gerapporteerde symptomen bevatten waarbij subjectieve interpretaties kunnen zijn ontstaan. De clusteringvalidteit geeft ons waardevolle inzichten maar validatie is beperkt omdat we hebben gekozen voor ene binaire dataafstandsmatrix en de Ward.D methode. Waardoor we een compacte cluster kregen. Het is niet wetenschappelijk onderbouwd waarom we hebben gekozen voor dit type clustering (op advies van chatgpt) We hebben enkel gekeken of er covid-19 symptomen aanwezig waren aangezien we er dan vanuit gingen dat men “suspected” of “confirmed” was. Dit is een aaname die we hebben gemaakt aangezien de dataset te complex ging worden voor dit project. De chi-kwadraat test toont geen siginificant verschil tussen de verschillende clusters van Covid-19 symptomen bij vrouwen met RRMMS.
```